Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen

被引：0
|
作者：
M. van Nuland
R. A. Vreman
R. M. T. ten Ham
A. H. M. de Vries Schultink
H. Rosing
J. H. M. Schellens
J. H. Beijnen
A. M. Hövels
机构：
[1] The Netherlands Cancer Institute and MC Slotervaart,Department of Pharmacy and Pharmacology
[2] The Netherlands Cancer Institute,Division of Pharmacology
[3] Utrecht University,Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences
[4] The Netherlands Cancer Institute,Division of Clinical Pharmacology, Department of Medical Oncology
来源：
Breast Cancer Research and Treatment | 2018年 / 172卷
关键词：
Therapeutic drug monitoring; Cost-effectiveness; Tamoxifen; Endoxifen; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：143 / 150
页数：7
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF MONITORING ENDOXIFEN LEVELS IN BREAST CANCER PATIENTS ADJUVANTLY TREATED WITH TAMOXIFEN
    Vreman, R.
    van Nuland, M.
    ten Ham, R. M.
    de Vries-Schultink, A. H.
    Rosing, H.
    Schellens, J. H.
    Beijnen, J. H.
    Hovels, A. M.
    VALUE IN HEALTH, 2018, 21 : S46 - S46
  • [2] Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen
    van Nuland, M.
    Vreman, R. A.
    ten Ham, R. M. T.
    Schultink, A. H. M. de Vries
    Rosing, H.
    Schellens, J. H. M.
    Beijnen, J. H.
    Hovels, A. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 172 (01) : 143 - 150
  • [3] Comparison of endoxifen levels between male and female breast cancer patients treated with tamoxifen.
    Lenehan, John Gordon
    Teft, Wendy A.
    Kim, Richard B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer
    Huang, Yaping
    Ke, Chengjie
    Cai, Jiaqin
    Wei, Xiaoxia
    Chen, Maohua
    Sun, Hong
    BREAST CANCER, 2024, 31 (05) : 917 - 925
  • [5] Association between tamoxifen and endoxifen plasma levels and clotting proteins in patients with primary breast cancer
    van Dorst, D.
    Buijs, S. M.
    Kruip, M. J. H. A.
    van den Akker, R. F. P.
    Cheung, K. L.
    Porrazzo, R.
    Oomen-de Hoop, E.
    Jager, A.
    Koolen, S. L.
    Versmissen, J.
    Danser, J. A. H.
    Versteeg, H. H.
    Bos, M. H. A.
    Mathijssen, R. H.
    ANNALS OF ONCOLOGY, 2023, 34 : S295 - S295
  • [6] Cost-Effectiveness of Chemoprevention of Breast Cancer Using Tamoxifen in a Postmenopausal US Population
    Noah-Vanhoucke, Joyce
    Green, Linda E.
    Dinh, Tuan A.
    Alperin, Peter
    Smith, Robert A.
    CANCER, 2011, 117 (15) : 3322 - 3331
  • [7] The cost effectiveness of tamoxifen in the prevention of breast cancer
    Noe, LL
    Becker, RV
    Gradishar, WJ
    Gore, M
    Trotter, JP
    AMERICAN JOURNAL OF MANAGED CARE, 1999, 5 (06): : S389 - S406
  • [8] Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
    Thomas Helland
    Nina Henne
    Ersilia Bifulco
    Bjørn Naume
    Elin Borgen
    Vessela N. Kristensen
    Jan T. Kvaløy
    Timothy L. Lash
    Grethe I. G. Alnæs
    Ron H. van Schaik
    Emiel A. M. Janssen
    Steinar Hustad
    Ernst A. Lien
    Gunnar Mellgren
    Håvard Søiland
    Breast Cancer Research, 19
  • [9] COST-EFFECTIVENESS OF ANASTROZOLE, IN COMPARISON WITH TAMOXIFEN, IN THE ADJUVANT TREATMENT OF EARLY BREAST CANCER IN BRAZIL
    Fonseca, Marcelo
    Araujo, Gabriela T. B.
    Saad, Everardo D.
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2009, 55 (04): : 410 - 415
  • [10] Canadian cost-effectiveness analysis of anastrozole versus tamoxifen in early breast cancer.
    Verma, S
    Rocchi, A
    Cheung, S
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S157 - S157
12345